Improved Nonalcoholic Steatohepatitis After 48 Weeks of Treatment With the Ppar–γ Ligand Rosiglitazone
Brent A. Neuschwander‐Tetri, Elizabeth M. Brunt, Kent R. Wehmeier et al. · Hepatology · 2003
Insulin resistance (IR) commonly is associated with nonalcoholic steatohepatitis (NASH). To establish whether IR causes NASH, this study was undertaken to determine if improving IR would improve the histologic features that define NASH. Thirty adults with prior biopsy evidence of NASH were enrolled to receive rosiglitazone, 4 mg twice daily for 48 weeks. All patients were overweight (body mass index [BMI] > 25 kg/m(2)) and 23% were severely obese (BMI > 35 kg/m(2)); 50% had impaired glucose tolerance or diabetes. Liver biopsy specimens were obtained before beginning treatment and at treatment completion. Twenty-six patients had posttreatment biopsies; of these, 22 had initial protocol liver biopsies that met published criteria for NASH on subsequent blinded evaluation. Within this initial NASH group, the mean global necroinflammatory score significantly improved with treatment and biopsies of 10 patients (45%) no longer met published criteria for NASH after treatment. Significant improvement in hepatocellular ballooning and zone 3 perisinusoidal fibrosis also occurred. Five patients withdrew early; the 25 patients completing 48 weeks of treatment had significantly improved insulin sensitivity and mean serum alanine aminotransferase (ALT) levels (104 initially, 42 U/L at the end of treatment). Adverse effects led to withdrawal of 3 patients (10%). Weight gain occurred in 67% of patients and the median weight increase was 7.3%. Within 6 months of completing treatment, liver enzyme levels had increased to near pretreatment levels. In conclusion, improving insulin sensitivity with rosiglitazone resulted in improved histologic markers of NASH, an observation suggesting that insulin resistance contributes to its development and that improving insulin sensitivity may be important in treating this liver disease.
Cited by 751 works. doi:10.1002/hep.1840380427 Open-access PDF
Authors
References
- Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin
- Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity☆, ☆☆
- Nonalcoholic Steatohepatitis: A Proposal for Grading and Staging The Histological Lesions
- The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation
- Quantitative Insulin Sensitivity Check Index: A Simple, Accurate Method for Assessing Insulin Sensitivity In Humans
- PPAR-γ agonists inhibit production of monocyte inflammatory cytokines
- Nonalcoholic Fatty Liver, Steatohepatitis, and the Metabolic Syndrome
- Television Watching and Other Sedentary Behaviors in Relation to Risk of Obesity and Type 2 Diabetes Mellitus in Women
- Regulation of the Hedgehog and Wingless signalling pathways by the F-box/WD40-repeat protein Slimb
- Nonalcoholic Steatohepatitis: Definition and Pathology